Schedule 13G ownership disclosure

Zentalis Pharmaceuticals, Inc.

Common Stock, $0.001 par value per share · CUSIP: 98943L107

Event date: 2025-12-18

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • 5AM Opportunities II (GP), LLC

    Shares: 3,947,913.00 · Class: 5.2%

  • 5AM Opportunities II, L.P.

    Shares: 3,947,913.00 · Class: 5.2%

  • 5AM Opportunities (GP), LLC

    Shares: 890,658.00 · Class: 1.2%

  • 5AM Opportunities Master Fund L.P.

    Shares: 890,658.00 · Class: 1.2%

  • Andrew J. Schwab

    Shares: 4,838,571.00 · Class: 6.4%

  • Kush Parmar

    Shares: 4,838,571.00 · Class: 6.4%

  • Anna Yaeger

    Shares: 890,658.00 · Class: 1.2%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001873515-25-000004
Form type
SCHEDULE 13G
Filer
5AM Opportunities II (GP), LLC
CIK
CIK 1873515
Filed
Dec 30, 2025
Reporting period
Dec 18, 2025
Description
Schedule 13G beneficial ownership

Explore SEC Filings Hub